ProPhase Labs, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 22:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $9.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $33.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-07-01 to 2021-09-30 | $5.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2021-01-01 to 2021-09-30 | $16.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-07-01 to 2021-09-30 | $4.0m | us-gaap:GrossProfit |
| Gross profit | 9 months2021-01-01 to 2021-09-30 | $17.4m | us-gaap:GrossProfit |
| Research and development | 3 months2021-07-01 to 2021-09-30 | $208.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-01-01 to 2021-09-30 | $416.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-07-01 to 2021-09-30 | −$3.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | −$3.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-07-01 to 2021-09-30 | $296.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2021-01-01 to 2021-09-30 | $870.0k | us-gaap:InterestExpense |
| Net income | 3 months2021-07-01 to 2021-09-30 | −$4.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | −$4.3m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | −$9.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-01-01 to 2021-09-30 | $4.3m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2021-01-01 to 2021-09-30 | $4.5m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2021-09-30 | $8.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-09-30 | $43.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $72.6m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $9.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $24.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-09-30 | $48.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-21-028235. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.